Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Join the brightest minds in regulatory at the annual Regulatory Convergence. See the global regulatory community in action. Intensive workshops. Topical sessions. Meet ups with regulators. This is where it all comes together.
For 20 years, our flagship publication, Fundamentals of US Regulatory Affairs, has been giving regulatory professionals the insights and answers they need, right at their fingertips.
There are hundreds of RAC testing centers available worldwide. Any of the four RAC exams (US, EU, CAN or Global) may be taken at any location. Find an upcoming exam at a location near you.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 19 March 2013 | By Alexander Gaffney, RAC,
The US Food and Drug Administration (FDA) has accused medical device manufacturer NuVasive of marketing its Affix Spinous Process Plate Systemic device without an approved application, rendering it misbranded and illegally marketed.
The allegations are contained within a 12 March 2013 warning letter sent to the company and made public on 19 March 2013. In it, regulators reference a 29 October 2012 investigation of the firm's San Diego, CA manufacturing facility.
"Our inspection revealed that the Affix Spinous Process Plate System is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g)," FDA wrote.
The orthopedic device has several cleared 510(k) applications, of which the relevant one (K073278) was found to be substantially equivalent to an earlier predicate device in March 2008.
At issue, FDA said, was that the device claims to be indicated for the "ILIF Surgical Technique" in which the Affix plate is used "as an adjunct to interbody fusion."
"Although your firm has multiple 510(k)s cleared for this device, none of them include the use of the Affix plate with only an intervertebral body fusion device," FDA explained. "This constitutes a new intended use and a new 510(k) is required in accordance with 21 CFR 807.81(a)(3)(ii)."
FDA's letter goes on to ask that the manufacturer stop marketing the device using the claim immediately and to respond to the letter within 15 days.
Tags: warning letter, medical device
Regulatory Focus newsletters
All the biggest regulatory news and happenings.